← Back to Companies

Arcutis Biotherapeutics

Commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with significant unmet medical needs.

Location
Westlake Village, California, USA
Founded
2016
Categories
biotech, dermatology, therapeutics, inflammation

Notes

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological conditions. The company's lead product ZORYVE (roflumilast) is an FDA-approved topical PDE4 inhibitor for the treatment of plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.

Arcutis employs a "follow-the-molecule" strategy, developing topical formulations of clinically proven active pharmaceutical ingredients (APIs) to address dermatological diseases with significant unmet medical needs. This approach leverages existing safety and efficacy data while developing novel formulations optimized for skin conditions.

The company is publicly traded on NASDAQ under the ticker symbol ARQT. Arcutis is backed by Bain Capital Life Sciences among other investors.

Team

  • Frank Watanabe - Founder, President & Chief Executive Officer
  • David Topper - Chief Financial Officer
  • John Smither - Chief Commercial Officer
  • Patrick Burnett, M.D., Ph.D. - Chief Medical Officer

Additional Research Findings

  • NASDAQ listed company (ARQT)
  • FDA-approved product ZORYVE (roflumilast) for psoriasis, seborrheic dermatitis, and atopic dermatitis
  • "Follow-the-molecule" development strategy
  • Focus on topical dermatology treatments
  • Backed by Bain Capital Life Sciences
  • Headquarters in Westlake Village, California
  • Founded 2016

Sources